Washington, Apr 25 : A new study has found that long-term treatment with Gamunex can significantly improve health-related quality of life in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
CIDP is a debilitating nerve disease that results in progressive weakness in the arms and legs, causing significant disability for many individuals.
Gamunex is the first and only FDA-approved product for the treatment of CIDP.
The researchers showed that patients who received Gamunex experienced greater improvements in physical and mental component scores compared with placebo.